Aligos Therapeutics, Inc. Common Stock ALGS
$3.95
-2.95%
at last close
Market Cap$25.42 million
P/E Ratio—
Div Yield—
Volume141.3K
52-Week Range
$3.95$13.69
Analyst Ratings
- Consensus
- Buy — 6 Buy · 0 Hold · 0 Sell (6 analysts)
- Avg. Price Target
- $38.50 (+874.7% upside)
Key Stats
- Today's Range
- $3.95 – $4.65
- 50-Day Range
- $3.95 – $6.83
- 52-Week Range
- $3.95 – $13.69
- Volume
- 141K shs
- Average Volume
- 37K shs
- Market Cap
- $25.42 million
- P/E Ratio
- —
- Dividend Yield
- —
Short Interest
- Short Interest
- 31.30%
- Days to Cover
- 4.10
About Aligos Therapeutics, Inc. Common Stock
Aligos Therapeutics Inc is a clinical-stage biotechnology company focused on developing therapeutics for liver diseases and viral infections. Its pipeline includes drug candidates targeting chronic hepatitis B virus (HBV) infection, metabolic dysfunction-associated steatohepatitis (MASH), obesity, and coronavirus infections, with programs such as pefivfoscorvir sodium for HBV, ALG-055009 for MASH and obesity, and ALG-097558 for coronavirus infections.
Related Stocks
Compare head-to-head: ALGS vs AMGN·ALGS vs MRNA·ALGS vs HALO·ALGS vs KYMR
Price and fundamental data are delayed and provided for informational purposes only. Not investment advice. See our disclaimer.